Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dunn

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
Epilepsy & Behavior : E&B|May 29, 2012
Depression and epilepsy, pain and psychogenic non-epileptic seizures: clinical and therapeutic perspectivesAndres M Kanner, Steven C Schachter, John J Barry, et al.
Journal of Clinical Epidemiology|March 30, 2010
Data linkage reduces loss to follow-up in an observational HIV cohort studyTeresa Hill, Loveleen Bansi, Caroline Sabin, et al.
Lancet (London, England)|December 11, 2007
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips, Clifford Leen, Alan Wilson, et al.
CMAJ Open|December 9, 2014
The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort studyMarina B Klein, Jim Young, David Dunn, et al.
BMJ (Clinical Research Ed.)|August 24, 2012
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study, David Dolling, Caroline Sabin, et al.
AIDS (London, England)|June 26, 2007
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie, Loveleen K Bansi, Caroline A Sabin, et al.
Antiviral Therapy|September 6, 2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr, David Back, David Dunn, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
Scientific Reports|September 20, 2016
A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and SwitzerlandManon L Ragonnet-Cronin, Mohaned Shilaih, Huldrych F Günthard, et al.
Health Technology Assessment (Winchester, England)|November 5, 2021
Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCTSam Barratt, Julia A Bielicki, David Dunn, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
Epilepsy & Behavior : E&B|May 29, 2012
Depression and epilepsy, pain and psychogenic non-epileptic seizures: clinical and therapeutic perspectivesAndres M Kanner, Steven C Schachter, John J Barry, et al.
Journal of Clinical Epidemiology|March 30, 2010
Data linkage reduces loss to follow-up in an observational HIV cohort studyTeresa Hill, Loveleen Bansi, Caroline Sabin, et al.
Lancet (London, England)|December 11, 2007
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort studyAndrew N Phillips, Clifford Leen, Alan Wilson, et al.
CMAJ Open|December 9, 2014
The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort studyMarina B Klein, Jim Young, David Dunn, et al.
BMJ (Clinical Research Ed.)|August 24, 2012
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study, David Dolling, Caroline Sabin, et al.
AIDS (London, England)|June 26, 2007
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failuresAndrew A Benzie, Loveleen K Bansi, Caroline A Sabin, et al.
Antiviral Therapy|September 6, 2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medicationWolfgang Stöhr, David Back, David Dunn, et al.
The Journal of Antimicrobial Chemotherapy|November 10, 2009
Factors influencing lopinavir and atazanavir plasma concentrationWolfgang Stöhr, David Back, David Dunn, et al.
Scientific Reports|September 20, 2016
A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and SwitzerlandManon L Ragonnet-Cronin, Mohaned Shilaih, Huldrych F Günthard, et al.
Health Technology Assessment (Winchester, England)|November 5, 2021
Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCTSam Barratt, Julia A Bielicki, David Dunn, et al.
Pageof 15